Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Phase 3ZenkudaKSI-501Neutral
AI Analysis
Summary
Kodiak Sciences will present topline results from the DAYBREAK Phase 3 study of Zenkuda and KSI-501 in wet age-related macular degeneration patients on September 28, 2026.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Topline results presentation scheduled
Importance:8/10
Sentiment:
0.00
Phase 3pivotal trialophthalmologyretinadata readout
Related Companies
Read the original article
Published by PR Newswire Biotech on September 25, 2026 10:01 PM